BioSpectrum Asia - July 2022Add to Favorites

BioSpectrum Asia - July 2022Add to Favorites

Magzter GOLDで読み攟題を利甚する

1 回の賌読で BioSpectrum Asia ず 8,500 およびその他の雑誌や新聞を読むこずができたす  カタログを芋る

1 ヶ月 $9.99

1 幎$99.99 $49.99

$4/ヶ月

保存 50% Hurry, Offer Ends in 9 Days
(OR)

のみ賌読する BioSpectrum Asia

1幎 $10.99

保存 7%

この号を賌入 $0.99

ギフト BioSpectrum Asia

7-Day No Questions Asked Refund7-Day No Questions
Asked Refund Policy

 ⓘ

Digital Subscription.Instant Access.

Digital Subscription
Instant Access

ⓘ

Verified Secure Payment

怜蚌枈み安党
支払い

ⓘ

この問題で

HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?
A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract evelopment and manufacturing organisations (CDMOs) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let’s navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system

Australia recommends COVID-19 booster for eligible 12-15 year old

Other vaccines such as Spikevax (Moderna) and Nuvaxovid (Novavax) are not registered for use as a booster for this age group.

Australia recommends COVID-19 booster for eligible 12-15 year old

1 min

Wuxi Biologics launches commercial drug product facility for PFS in China

The DP5 is the ninth operational drug product facility in the global network of Wuxi Biologics.

Wuxi Biologics launches commercial drug product facility for PFS in China

1 min

CEPI, Oxford Vaccine Group evaluate fractional COVID-19 booster vaccines

Trial participants include those who already have received a primary regimen of two doses of CoronaVac at least six months prior to joining the study.

CEPI, Oxford Vaccine Group evaluate fractional COVID-19 booster vaccines

1 min

US picks interdisciplinary teams to address major challenges in cancer

Cancer Grand Challenges aims to provide multiple rounds of funding for multidisciplinary research teams from around the world whose novel ideas have the greatest potential to advance cancer research and improve outcomes for people affected by cancer.

US picks interdisciplinary teams to address major challenges in cancer

1 min

HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?

A successful business model for the pharmaceutical industry is driven by the outsourcing trend, making contract development and manufacturing organisations (CDMOS) an integral component of drug development value chains. Increasing regulatory complexity, high development costs, and fierce competition have driven drug companies to leverage CDMOs to accelerate their go-to-market strategy, and Asia Pacific (APAC) is not an exception. Let's navigate through prime achievements and potential trends in the APAC CDMO arena which helped the world heal during the pandemic and is further helping to build a resilient health system.

HOW IS BIOMANUFACTURING DRIVING CDMO MARKET?

10 mins

Eschewing Myopic Attitude Towards Eye Health

Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.

Eschewing Myopic Attitude Towards Eye Health

9 mins

Why Indian Pharma Must Evolve As 'Value Creator'

As the third-largest drug producer in the world, India is already a major global pharmaceutical player. However, when it comes to the value of production, India ranks fourteenth. A deeper dive into the details reveals an important fact: India is the largest producer and supplier of generic medicines globally, delivering a 20 per cent share. India's pharmaceutical sector has the highest number of USFDA-approved manufacturing plants outside the USA, 3,000 pharmaceutical companies, a network of 10,500 manufacturing facilities and a rich talent pool. So, why does it lag so significantly in deriving value from its assets? Is there an opportunity for the Indian pharmaceutical industry to evolve in a way that moves India up on the value scale by increasing innovation - and what will it take? Let's find out.

Why Indian Pharma Must Evolve As 'Value Creator'

4 mins

Obstructive Sleep Apnea brings about a severe economic burden on the country

India has over 50 million sleep apnea patients, 80 per cent of whom are undiagnosed, as per the Lancet Respiratory Medicine 2019 study. Considering the prevalence, OSA brings about a severe economic burden on the country in such a situation. When it comes to COPD, it is the second leading cause of death worldwide, affecting more than 53 million from India. Due to the vulnerability of the lungs, COPD patients become prone to developing cardiovascular issues, and lung cancer, in case of acute exacerbations and even premature death.

Obstructive Sleep Apnea brings about a severe economic burden on the country

5 mins

Spending on TB control programmes had dropped to 2016 levels in 2020 and remains unchanged

Contrary to popular opinion, tuberculosis (TB) has not been eliminated in Singapore.

Spending on TB control programmes had dropped to 2016 levels in 2020 and remains unchanged

4 mins

Regulatory bottlenecks such as local QC testing and pre-approval of GMP inspections must go

The APAC pharma and biopharma landscape is rapidly evolving and the market access landscape is increasingly turning complex with the intricate regulatory system.

Regulatory bottlenecks such as local QC testing and pre-approval of GMP inspections must go

5 mins

Leveraging big data to create transparency, mitigate risks and operate in real-time is critical

With the innovation boom in Asia and many early-stage assets emerging, the time is ripe for Asian economies to establish cross-border business relationships by systematically tapping potential markets for successful market penetration.

Leveraging big data to create transparency, mitigate risks and operate in real-time is critical

5 mins

From Hazy to Crystal Clear Picture of Compensation Trends

The Life Sciences industry is, indeed, growing at a rapid speed, with every region reporting bonuses and salary increments, as well as a high demand in recruiting new talent. With the talent market becoming increasingly hot, it is critical for industry hiring managers and companies to stay highly aware of compensation trends in the Asia Pacific (APAC) region. Let's assess the current scenario to get a handle on 'what's changed'.

From Hazy to Crystal Clear Picture of Compensation Trends

5 mins

BioSpectrum Asia の蚘事をすべお読む

BioSpectrum Asia Magazine Description:

出版瀟: MM Activ Sci-Tech Communication

カテゎリヌ: Business

蚀語: English

発行頻床: Monthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

  • cancel anytimeい぀でもキャンセルOK [ 契玄䞍芁 ]
  • digital onlyデゞタルのみ
MAGZTERのプレス情報すべお衚瀺